

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**203168Orig1s000**

**MICROBIOLOGY REVIEW(S)**

# Product Quality Microbiology Review

17 January 2013

**NDA:** NDA 203-168/N-000

**Drug Product Name**

**Proprietary:** Prolensa™ 0.07%

**Non-proprietary:** bromfenac ophthalmic solution

**Review Number:** 1

**Dates of Submission(s) Covered by this Review**

Submit	Received	Review Request	Assigned to Reviewer
6 June 2012	7 June 2012	22 June 2012	28 June 2012
16 November 2012	19 November 2012	N/A	N/A
19 December 2012	19 December 2012	N/A	N/A

**Submission History (for amendments only):** Not applicable

**Applicant/Sponsor**

**Name:** ISTA Pharmaceuticals

**Address:** 50 Technology  
Irvine, CA 92618

**Representative:** Paul Nowacki

**Telephone:** 949-789-3109

**Name of Reviewer:** Stephen E. Langille, Ph.D.

**Conclusion:** Recommended for approval

## Product Quality Microbiology Data Sheet

- A.
1. **TYPE OF SUBMISSION:** Original submission- priority review
  2. **SUBMISSION PROVIDES FOR:** (b) (4) information for a sterile topical ophthalmic drug product.
  3. **MANUFACTURING SITE:** Bausch and Lomb Pharmaceuticals, Inc.  
8500 Hidden River Parkway  
Tampa, FL 33637  
Registration Number 1052807
  4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:**
    - Sterile solution in an LDPE (b) (4) round bottle
    - Topical Ophthalmic
    - 0.07%
  5. **METHOD(S) OF STERILIZATION:** (b) (4)
  6. **PHARMACOLOGICAL CATEGORY:** Ophthalmic analgesic
- B. **SUPPORTING/RELATED DOCUMENTS:** None
- C. **REMARKS:** The submission was provided in eCTD format. The following information requests were sent to the applicant on 1 November 2012 and 6 November 2012.

1. *Provide a justification for* (b) (4)

(b) (4)

2. *Provide a copy of* (b) (4)

(b) (4)

(b) (4)

3. Provide the raw data (plate counts) for the preservative effectiveness test results provided in tables J3-1, J3-2, and J3-3 located in the "Preservative Effectiveness Tests and Methods" document located in section 3.2.P.3.5 of the application.

4. Provide the following information regarding endotoxin testing for Prolensa™

- a. The endotoxin limit for the drug product (an endotoxin limit of (b) (4) is suggested)
- b. The test method to be used for endotoxin testing
- c. Calculation of the maximum valid dilution
- d. The results of inhibition/enhancement testing
- e. Inclusion of the endotoxin limit and test method in the list of drug product specifications.

Responses to the information requests were provided on 16 November 2012 and 19 December 2012 and have been incorporated into the body of this review.

**filename:** N203168r1.doc

## **Executive Summary**

### **I. Recommendations**

#### **A. Recommendation on Approvability -**

NDA 203-168/N-000 is recommended for approval from the standpoint of product quality microbiology.

#### **B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable -**

Not applicable

### **II. Summary of Microbiology Assessments**

#### **A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology -**

The drug product will be (b) (4) at the Bausch and Lomb Tampa, FL facility.

#### **B. Brief Description of Microbiology Deficiencies -**

No product quality microbiology deficiencies were identified based upon the information provided.

#### **C. Assessment of Risk Due to Microbiology Deficiencies -**

Not applicable.

### **III. Administrative**

#### **A. Reviewer's Signature**

\_\_\_\_\_  
Stephen E. Langille, Ph.D.  
Senior Microbiology Reviewer

#### **B. Endorsement Block**

\_\_\_\_\_  
Bryan Riley, Ph.D.  
Senior Microbiology Reviewer

#### **C. CC Block**

N/A

13 Pages have been Withheld in Full as b4 (CCI/TS) immediately following this page.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.